No Data
Luzhu Bio-B (02480) bought back 3400 shares on July 16th.
Green Bamboo Biotech-B (02480) announced that it will spend HKD 0.083 million to repurchase 34... on July 16, 2024.
On July 15th, Luye Pharma Group Ltd-B (02480.HK) spent HKD 28.174 million to repurchase 1.1544 million shares.
On July 15th, Green Bamboo Biological-B (02480.HK) announced the repurchase of 1.1544 million shares for HKD 28.174 million.
On July 12th, Green Bamboo Biotech -B (02480.HK) spent 6.63 million Hong Kong dollars to repurchase 0.278 million shares.
On July 12th, Gelonhui reported that Lvshe Biology-B (02480.HK) spent 6.63 million Hong Kong dollars to buy back 0.278 million shares on July 12, 2024, with a buyback price of 23.45-24.05 Hong Kong dollars per share.
With a daily trading volume of only 3200 shares, Green Bamboo Biopharmaceutical-B (02480), which holds a heavyweight vaccine, has fallen into a liquidity crisis.
The earliest time for Lvzhushengwu to introduce its first commercial product will be the end of next year, and the lack of a commercial product as a valuation anchor means that the company's stock price is susceptible to market fluctuations until the R&D milestones are clearly identified to strengthen its market research and valuation.
LUZHU BIOTECH-B: Annual Report 2023
Luzhu Bio-B (02480.HK)'s annual adjusted loss increased by about 46.6% to about 223 million yuan
On March 15, GLONGHUI | Green Bamboo Bio-B (02480.HK) announced that the Group's other revenue increased by about 44.3% from approximately RMB 13.9 million for the year ended December 31, 2022 to approximately RMB 20.1 million for the year ended December 31, 2023, mainly due to an increase in bank balance interest income of about RMB 5.8 million due to an increase in the Group's bank deposits. The Group's R&D expenditure increased by approximately 88.9% from approximately RMB 91.4 million for the year ended December 31, 2022 to December 31, 2023
No Data
